Salinomycin: A new paradigm in cancer therapy

Tumor Biology

Volumn 39, Issue 3, 2017, Pages

  Dewangan, Jayant ^a   Srivastava, Sonal ^a   Rath, Srikanta Kumar ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

cancer; cancer stem cells; multidrug resistance; Salinomycin

Indexed keywords

CISPLATIN; COLCHICINE; CYTARABINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IMATINIB; LAPATINIB; METFORMIN; NANOPARTICLE; PACLITAXEL; POLYGLACTIN; SALINOMYCIN; SALINOMYCIN DERIVATIVE; TRASTUZUMAB; VERAPAMIL; VINBLASTINE; PYRAN DERIVATIVE; TUMOR PROTEIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; DIZZINESS; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; DYSPNEA; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HYPERTENSION; LIMB WEAKNESS; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; NASOPHARYNX CARCINOMA; NAUSEA; NONHUMAN; OSTEOSARCOMA; OXIDATIVE STRESS; PHOTOPHOBIA; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; NEOPLASMS; PATHOLOGY; WNT SIGNALING PATHWAY;

APOPTOSIS; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASTIC STEM CELLS; PYRANS; WNT SIGNALING PATHWAY;

EID: 85016924820     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1177/1010428317695035     Document Type: Review

References (105)

1. Miyazaki Y, Shibuya M, Sugawara H. Salinomycin, a new polyether antibiotic. J Antibiot 1974; 27: 814–821.
2. Fuchs D, Heinold A, Opelz G. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun 2009; 390: 743–749.
3. Mitani M, Yamanishi T, Miyazaki Y. Salinomycin effects on mitochondrial ion translocation and respiration. Antimicrob Agents Chemother 1976; 9: 655–660.
4. Danforth HD, Ruff MD, Reid WM. Anticoccidial activity of salinomycin in battery raised broiler chickens. Poult Sci 1977; 56: 926–932.
5. Mehlhorn H, Ganster HJ, Raether W. Effect of salinomycin-Na on malaria parasites (Plasmodium falciparum and P. berghei). Zentralbl Bakteriol Mikrobiol Hyg A 1984; 256: 305–313.
6. Cann IK, Kobayashi Y, Onoda A. Effects of some ionophore antibiotics and polyoxins on the growth of anaerobic rumen fungi. J Appl Bacteriol 1993; 74: 127–133.
7. Gupta PB, Onder TT, Jiang G. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645–659.
8. Zhou S, Wang F, Wong ET. Salinomycin: a novel anti-cancer agent with known anti-coccidial activities. Curr Med Chem 2013; 20: 4095–4101.
9. Antoszczak M, Huczynski A., Anticancer activity of polyether ionophore-salinomycin. Anticancer Agents Med Chem 2015; 15: 575–591.
10. Riccioni R, Dupuis ML, Bernabei M. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis 2010; 45: 86–92.
11. Huczynski A, Janczak J, Antoszczak M. Antiproliferative activity of salinomycin and its derivatives. Bioorg Med Chem Lett 2012; 22: 7146–7150.
12. Zhang G, Zhang X., Multidrug resistance and breast cancer. In: Aft R (ed.) Targeting new pathways and cell death in breast cancer, 2012, pp. 131–156.
13. Kickhoefer VA, Rajavel KS, Scheffer GL. Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem 1998; 273: 8971–8974.
14. Ullah MF., Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev 2008; 9: 1–6.
15. Gottesman MM., Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615–627.
16. Goldstein LJ, Galski H, Fojo A. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116–124.
17. Doyle L, Ross DD., Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 7340–7358.
18. Borst P, Evers R, Kool M. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295–1302.
19. Szakacs G, Paterson JK, Ludwig JA. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219–234.
20. Wind NS, Holen I., Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int J Breast Cancer 2011; 2011: 967419.
21. Nygren P, Larsson R, Gruber A. Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression. Br J Cancer 1991; 64: 1011–1018.
22. Izquierdo MA, Neefjes JJ, Mathari AE. Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. Br J Cancer 1996; 74: 1961–1967.
23. Naujokat C, Steinhart R., Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol 2012; 2012: 950658.
24. Liu R, Wang X, Chen GY. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007; 356: 217–226.
25. Singh A, Settleman J., Emt, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741–4751.
26. Karsten U, Goletz S., What makes cancer stem cell markers different? SpringerPlus 2013; 2: 301.
27. Zhou J, Li P, Xue X. Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactive oxygen species. Toxicol Lett 2013; 222: 139–145.
28. Bao F, Polk P, Nordberg ML. Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res 2007; 31: 1511–1520.
29. Sahlberg SH, Spiegelberg D, Glimelius B. Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells. PLoS ONE 2014; 9: e94621.
30. Fredebohm J, Boettcher M, Eisen C. Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system. PLoS ONE 2012; 7: e48503.
31. Taipale J, Beachy PA., The Hedgehog and Wnt signalling pathways in cancer. Nature 2001; 411: 349–354.
32. Yeung J, Esposito MT, Gandillet A. β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010; 18: 606–618.
33. Reya T, Morrison SJ, Clarke MF. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105–111.
34. Nakashima H, Nakamura M, Yamaguchi H. Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res 2006; 66: 7041–7049.
35. Kim RJ, Bae E, Hong YK. PTEN loss-mediated Akt activation increases the properties of cancer stem-like cell populations in prostate cancer. Oncology 2014; 87: 270–279.
36. Aksamitiene E, Kiyatkin A, Kholodenko BN., Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans 2012; 40: 139–146.
37. Ketola K, Hilvo M, Hyotylainen T. Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Cancer 2012; 106: 99–106.
38. Choi H-J, Kim K-Y, Yu S-N. Salinomycin-induced apoptosis in human prostate cancer cells, 2013, http://cdn.intechopen.com/pdfs/41811/InTech-Salinomycin_induced_apoptosis_in_human_prostate_cancer_cells.pdf
39. Basu D, Montone KT, Wang LP. Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle 2011; 10: 2008–2016.
40. Wang F, He L, Dai WQ. Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS ONE 2012; 7: e50638.
41. Jangamreddy JR, Ghavami S, Grabarek J. Salinomycin induces activation of autophagy, mitophagy and affects mitochondrial polarity: differences between primary and cancer cells. Biochim Biophys Acta 1833; 2013: 2057–2069.
42. Wu D, Zhang Y, Huang J. Salinomycin inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cell in vitro and suppresses tumor growth in vivo. Biochem Biophys Res Commun 2014; 443: 712–717.
43. Arafat K, Iratni R, Takahashi T. Inhibitory effects of salinomycin on cell survival, colony growth, migration, and invasion of human non-small cell lung cancer a549 and lnm35: involvement of nag-1. PLoS ONE 2013; 8: e66931.
44. Lieke T, Ramackers W, Bergmann S. Impact of salinomycin on human cholangiocarcinoma: induction of apoptosis and impairment of tumor cell proliferation in vitro. BMC Cancer 2012; 12: 466.
45. Kim JH, Kim TY, Kim HS. Lower salinomycin concentration increases apoptotic detachment in high-density cancer cells. Int J Mol Sci 2012; 13: 13169–13182.
46. Kaplan F, Teksen F., Apoptotic effects of salinomycin on human ovarian cancer cell line (ovcar-3). Tumour Biol 2016; 37: 3897–3903.
47. Li T, Liu X, Shen Q. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis. Oncotarget 2016; 7: 26580–26592.
48. He M, Fu Y, Yan Y. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients. Clin Sci 2015; 129: 809–822.
49. An H, Kim JY, Oh E. Salinomycin promotes anoikis and decreases the CD44+/CD24− stem-like population via inhibition of STAT3 activation in MDA-MB-231 cells. PLoS ONE 2015; 10: e0141919.
50. Kim JH, Chae M, Kim WK. Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br J Pharmacol 2011; 162: 773–784.
51. Li T, Su L, Zhong N. Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells. Autophagy 2013; 9: 1057–1068.
52. Tang QL, Zhao ZQ, Li JC. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett 2011; 311: 113–121.
53. Kuo SZ, Blair KJ, Rahimy E. Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt. BMC Cancer 2012; 12: 556.
54. Koo KH, Kim H, Bae YK. Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2. Cell Death Dis 2013; 4: e693.
55. Liu PP, Zhu JC, Liu GX. Salinomycin enhances the apoptosis of t-cell acute lymphoblastic leukemia cell line Jurkat cells induced by vincristine. Zhongguo Shi Yan Xue Te Xue Za Zhi 2015; 23: 653–657.
56. Fuchs D, Daniel V, Sadeghi M. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun 2010; 394: 1098–1104.
57. Lu D, Choi MY, Yu J. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A 2011; 108: 13253–13257.
58. Mao J, Fan S, Ma W. Roles of Wnt/β-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment. Cell Death Dis 2014; 5: e1039.
59. Kusunoki S, Kato K, Tabu K. The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells. Gynecol Oncol 2013; 129: 598–605.
60. Jangamreddy JR, Jain MV, Hallbeck AL. Glucose starvation-mediated inhibition of salinomycin induced autophagy amplifies cancer cell specific cell death. Oncotarget 2015; 6: 10134–10145.
61. McCarthy JV, Cotter TG., Cell shrinkage and apoptosis: a role for potassium and sodium ion efflux. Cell Death Differ 1997; 4: 756–770.
62. Kim WK, Kim JH, Yoon K. Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. Invest New Drugs 2012; 30: 1311–1318.
63. Verdoodt B, Vogt M, Schmitz I. Salinomycin induces autophagy in colon and breast cancer cells with concomitant generation of reactive oxygen species. PLoS ONE 2012; 7: e44132.
64. Lu Y, Ma W, Mao J. Salinomycin exerts anticancer effects on human breast carcinoma MCF-7 cancer stem cells via modulation of hedgehog signaling. Chem Biol Interact 2015; 228: 100–107.
65. Nicosia RF, Bonanno E, Smith M., Fibronectin promotes the elongation of microvessels during angiogenesis in vitro. J Cell Physiol 1993; 154: 654–661.
66. Francis SE, Goh KL, Hodivala-Dilke K. Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol 2002; 22: 927–933.
67. Kalluri R, Weinberg RA., The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420–1428.
68. Voulgari A, Pintzas A., Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009; 1796: 75–90.
69. Qu H, Ma B, Yuan HF. Effect of salinomycin on metastasis and invasion of bladder cancer cell line T24. Asian Pac J Trop Med 2015; 8: 578–582.
70. Sanchez-Tillo E, Fanlo L, Siles L. The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. Cell Death Differ 2014; 21: 247–257.
71. Koeck S, Amann A, Huber JM. The impact of metformin and salinomycin on transforming growth factor β-induced epithelial-to-mesenchymal transition in non-small cell lung cancer cell lines. Oncol Lett 2016; 11: 2946–2952.
72. Zhou Y, Liang C, Xue F. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation. Oncotarget 2015; 6: 10350–10365.
73. Zhang C, Lu Y, Li Q. Salinomycin suppresses TGF-β1-induced epithelial-to-mesenchymal transition in MCF-7 human breast cancer cells. Chem Biol Interact 2016; 248: 74–81.
74. Sharma S, Kelly TK, Jones PA., Epigenetics in cancer. Carcinogenesis 2010; 31: 27–36.
75. Kanwal R, Gupta S., Epigenetic modifications in cancer. Clin Genet 2012; 81: 303–311.
76. Gao FH, Hu XH, Li W. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer 2010; 10: 610.
77. Al Dhaheri Y, Attoub S, Arafat K. Salinomycin induces apoptosis and senescence in breast cancer: upregulation of p21, downregulation of survivin and histone H3 and H4 hyperacetylation. Biochim Biophys Acta 2013; 1830: 3121–3135.
78. Singh AK, Maheshwari S, Arya RK. Salinomycin targets EZH2 driven epigenetic repression of death receptors in colon cancer stem cells. In: NCRI cancer conferences, 2015, http://abstracts.ncri.org.uk/abstract/salinomycin-targets-ezh2-driven-epigenetic-repression-of-death-receptors-in-colon-cancer-stem-cells-2/
79. Henry JC, Park JK, Jiang J. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2010; 403: 120–125.
80. Fornari F, Milazzo M, Chieco P. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2010; 70: 5184–5193.
81. Pan YZ, Morris ME, Yu AM., MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 2009; 75: 1374–1379.
82. Saini S, Majid S, Yamamura S. Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res 2011; 17: 5287–5298.
83. Ivanova J, Pantcheva IN, Zhorova R. Synthesis, spectral properties, antibacterial and antitumor activity of salinomycin complexes with the transition metal ions Co(II), Ni(II), Cu(II) and Zn(II). J Chem Chem Eng 2012; 6: 551–562.
84. Muntimadugu E, Kumar R, Saladi S. CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel. Colloids Surf B: Biointerfaces 2016; 143: 532–546.
85. Tigli Aydin RS, Kaynak G, Gumusderelioglu M., Salinomycin encapsulated nanoparticles as a targeting vehicle for glioblastoma cells. J Biomed Mater Res A 2016; 104: 455–464.
86. Niwa AM, D Epiro GF, Marques LA. Salinomycin efficiency assessment in non-tumor (HB4a) and tumor (MCF-7) human breast cells. Naunyn Schmiedebergs Arch Pharmacol 2016; 389: 557–571.
87. Ojo OO, Bhadauria S, Rath SK., Dose-dependent adverse effects of salinomycin on male reproductive organs and fertility in mice. PLoS ONE 2013; 8: e69086.
88. Aleman M, Magdesian KG, Peterson TS. Salinomycin toxicosis in horses. J Am Vet Med Assoc 2007; 230: 1822–1826.
89. Bezerra PS, Driemeier D, Loretti AP. Monensin poisoning in Brazilian horses. Vet Hum Toxicol 1999; 41: 383–385.
90. Van Assen EJ. A case of salinomycin intoxication in turkeys. Can Vet J 2006; 47: 256–258.
91. Boehmerle W, Endres M., Salinomycin induces calpain and cytochrome c-mediated neuronal cell death. Cell Death Dis 2011; 2: e168.
92. Plumlee KH, Johnson B, Galey FD., Acute salinomycin toxicosis of pigs. J Vet Diagn Invest 1995; 7: 419–420.
93. Oak PS, Kopp F, Thakur C. Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets her2-positive cancer cells and cancer stem cells. Int J Cancer 2012; 131: 2808–2819.
94. Liffers ST, Tilkorn DJ, Stricker I. Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas. BMC Cancer 2013; 13: 490.
95. Zhang GN, Liang Y, Zhou LJ. Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. Cancer Lett 2011; 313: 137–144.
96. Daman Z, Montazeri H, Azizi M. Polymeric micelles of PEG-PLA copolymer as a carrier for salinomycin against gemcitabine-resistant pancreatic cancer. Pharm Res 2015; 32: 3756–3767.
97. Bardsley MR, Horvath VJ, Asuzu DT. Kit(low) stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 2010; 139: 942–952.
98. Zhang Y, Zhang H, Wang X. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 2012; 33: 679–691.
99. Gong C, Yao H, Liu Q. Markers of tumor-initiating cells predict chemoresistance in breast cancer. PLoS ONE 2010; 5: e15630.
100. Kim JH, Choi AR, Kim YK. Low amount of salinomycin greatly increases Akt activation, but reduces activated p70S6K levels. Int J Mol Sci 2013; 14: 17304–17318.
101. Aydin RS., Herceptin-decorated salinomycin-loaded nanoparticles for breast tumor targeting. J Biomed Mater Res A 2013; 101: 1405–1415.
102. Kumar R, Yarmand-Bagheri R., The role of HER2 in angiogenesis. Semin Oncol 2001; 28: 27–32.
103. Alameddine RS, Otrock ZK, Awada A. Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges. Curr Opin Oncol 2013; 25: 313–324.
104. Zou ZZ, Nie PP, Li YW. Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer. Oncotarget. Epub ahead of print 7 October 2015. DOI: 10.18632/oncotarget.5628.
105. Kai M, Kanaya N, Wu SV. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin. Breast Cancer Res Treat 2015; 151: 281–294.